How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
Description:
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction
Sponsor:
SmartNuclide Biopharma
Government Study Link:
NCT06646783 - Click here to see study onClinicalTrials.gov
[68Ga]Ga-NODAGA-SNA014
Isotope(s):
Target(s):
- Claudin 18.2
